Millimeter wave treatment induces apoptosis via activation of the mitochondrial-dependent pathway in human osteosarcoma cells

GUANGWEN WU[1], XUZHENG CHEN[1], JUN PENG[2], QIAOYAN CAI[2], JINXIA YE[2], HUIFENG XU[3], CHUNSONG ZHENG[1], XIHAI LI[1], HONGZHI YE[1] and XIANXIANG LIU[1]

[1]Academy of Integrative Medicine; [2]Academy of Integrative Medicine Biomedical Research Center; [3]Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, P.R. China

Received November 3, 2011; Accepted December 19, 2011

DOI: 10.3892/ijo.2012.1330

RETRACTED

Abstract. Millimeter wave (MW) is an electromagnetic wave with a wavelength between 1 and 10 mm and a frequency of 30-300 GHz that causes multiple biological effects and has been used as a major component in physiotherapies for the clinical treatment of various types of diseases including cancers. However, the precise molecular mechanism of the anticancer activity of millimeter wave remains to be elucidated. In the present study, we investigated the cellular effects of the MW in the U-2OS human osteosarcoma cell line. Our results showed that MW induced cell morphological changes and reduced cell viability in a dose- and time-dependent manner suggesting that MW inhibited the growth of U-2OS cells as demonstrated. Hoechst 33258 staining and Annexin V/propidium iodide double staining exhibited the typical nuclear features of apoptosis and increased the proportion of apoptotic Annexin V-positive cells in a dose-dependent manner, respectively. In addition, MW treatment caused loss of plasma membrane asymmetry, release of cytochrome *c*, collapse of mitochondrial membrane potential, activation of caspase-9 and -3, and increase of the ratio of pro-apoptotic Bax to anti-apoptotic Bcl-2. Taken together, the results indicate that the U-2OS cell growth inhibitory activity of MW was due to mitochondrial-mediated apoptosis, which may partly explain the anticancer activity of millimeter wave treatment.

Introduction

Human osteosarcoma (OS) is the most common primary malignant bone tumor, accounting for approximately 20% of all primary sarcomas in bone (1). It occurs predominantly in adolescents and young adults (2). Well-known for its metastasis and high local recurrence rate (3,4), osteosarcoma is a type of cancer whose treatment requires an extensive multimodal approach including surgery, radiotherapy and chemotherapy.

Currently, chemotherapeutic regimens for human osteosarcoma treatment use combination of multiple chemotherapeutic agents including high-dose methotrexate (HD-MTX) with leucovorin rescue, doxorubicin (adriamycin), cisplatin, and ifosfamide either with or without etoposide (5). Although new therapies consisting of aggressive adjuvant chemotherapy and wide tumor excision have led to a significant benefit in terms of patients' survival, the frequent acquisition of drug-resistant phenotypes and unwanted side effects are often associated with chemotherapy and remain as serious problems (6). Moreover, many currently used chemo-therapeutic agents for cancer therapy have potent cytotoxic effects in normal cells and may induce DNA mutations that probably lead to secondary cancers (7). Therefore, new therapeutic strategies which can improve the effect of current chemotherapy need to be developed.

A millimeter wave (MW) is an electromagnetic wave with a wavelength between 1 and 10 mm and a frequency of 30-300 GHz. Organisms produce coherent oscillations at $0.5x10^{10}$-$3x10^{12}$ during metabolism similar to the frequency of a millimeter wave. Therefore, the energy of a millimeter wave can be absorbed by the organism through resonance. In turn, the energy can interfere with signal transduction and affect metabolism (8-10). It has been shown that a millimeter wave can evoke multiple biological effects (11,12) and is useful in the treatment of various types of diseases including cancers, such as hepatic cellular cancer patient (13,14). However, the effects of MW on the growth and apoptosis of human osteosarcoma U-2OS cells, have not yet been reported.

Apoptosis is a genetically mediated mechanism by which individual cells orchestrate their own deletion in normal and diseased tissues. It is a complex process which includes signal transduction (15) and the degradation of cellular protein and DNA (16). Disturbed regulation of this vital process represents a major causative factor in the pathogenesis of cancers including osteosarcoma (17,18). The Bcl-2 family proteins are important regulators of apoptosis including both anti-apoptotic members such as Bcl-2 and pro-apoptotic members such as Bax (17,18).

Correspondence to: Dr Xianxiang Liu, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, 1 Huatuo Road, Shangjie Minhou, Fuzhou 350108, P.R. China
E-mail: liuxianxiang@163.com

Abbreviations: OS, osteosarcoma; MW, millimeter wave; FBS, fetal bovine serum; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate buffered saline; MTT, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide; DMSO, dimethyl sulfoxide

Key words: osteosarcoma cell, millimeter wave, apoptosis, mitochondria

One possible mechanism by which Bcl-2 family proteins regulate apoptosis is through their influence on the permeability of mitochondrial outer membrane (MOM) following homo- or hetero-association (19). It has been demonstrated that after activation, the pro-apoptotic Bax or Bak is sufficient to induce mitochondrial outer membrane permeabilization (MOMP) (20-22), releasing apoptogenic proteins such as cytochrome *c*, Smac/DIABLO and apoptosis inducing factor (AIF) (22-25). The released cytochrome *c* leads to apoptotic protease-activating factor (Apaf-1)-mediated activation of initiator caspase-9, which in turn activates effector caspases (26). Anti-apoptotic Bcl-2 proteins have been reported to protect cells from many different apoptotic stimuli and are important for cell survival (27-29) and may bind to active Bax to prevent it from damaging the MOM (20,25,30,31). The balance of active anti- and pro-apoptotic Bcl-2 family members determines the fate of cells, and alteration of the ratio by aberrant expression of these proteins impairs the normal apoptotic program contributing to various apoptosis-related diseases (32,33). For instance, overexpression of Bcl-2 is commonly found in various cancers (34), which not only confers a survival advantage to the cancer cells but also causes resistance to conventional chemo- and radio-therapies. Therefore, promoting cell apoptosis through regulating the Bcl-2 family proteins has been the main focus in the development of anti-cancer therapies.

In order to extend the clinical observations of the potential anti-cancer effect of MW and help to establish a scientific foundation for further research, in this study, we evaluated the cellular effect of the MW on the growth and apoptosis of U-2OS human osteosarcoma cells, and investigated the possible molecular mechanisms mediating its biological effect. We found that MW inhibited the growth and induced apoptosis of U-2OS cells. MW-induced apoptosis was accompanied by loss of mitochondrial membrane potential ($\Delta\Psi_m$), release of cytochrome *c*, activation of caspase-9 and -3 and up-regulation of Bax to Bcl-2 ratio. Our finding suggests that promotion of cancer cell apoptosis through activation of the mitochondrion-dependent pathway is one of the mechanisms by which MW can be effective in the treatment of cancer.

Materials and methods

Materials and reagents. Fetal bovine serum (FBS), Dulbecco's modified Eagle's medium (DMEM), and trypsin were purchased from Hyclone Laboratories, Inc. (Logan, UT, USA). 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and Hoechst 33258 were obtained from Sigma Chemical Co. (St. Louis, MO, USA). An apoptosis assay (Annexin V-FITC Apoptosis Dection Kit II) was provided by Becton-Dickinson (San Jose, CA, USA). A JC-1 mitochondrial membrane potential detection assay was obtained from Biotium, Inc. (Hayward, CA, USA). The flow cytometric cytochrome *c* release assay (InnoCyte kit) was purchased from EMD Chemicals, Inc. (Darmstadt, Germany). Caspase-9 and -3 colorimetric protease assays were obtained from Invitrogen Inc. (Grand Island, NY, USA). The TaqMan Universal PCR Master Mix Kit, Bcl-2, Bax and GAPDH primer were purchased from AB Applied Biosystems (Foster, CA, USA). Chemiluminescent western blot immunodetection kit was obtained from Invitrogen Inc. (Grand Island, NY, USA). Bcl-2, Bax antibodies, horseradish peroxidase (HRP)-conjugated secondary antibodies and antibody against β-actin were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA).

MW stimulation. AKFA-100A millimeter wave therapeutic instrument (incidence power density: 4 mw/cm^2; wavelength coverage: 7.5-10.0 mm) was manufactured by Beijing Zhongchengkangfu Technology Co. Ltd. (Beijing, China). As illustracted in Fig. 1, the detecting head of the instrument (radiation source) was positioned 30 mm above the cells (cultured in MW treatment group), which can ensure that all the cells are within the radiation area of 33.2±3 x 45.6±4 mm.

Cell culture. Human osteosarcoma U-2OS cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were grown in DMEM containing 10% (v/v) FBS and 100 U/ml penicillin and 100 μg/ml streptomycin in a 37˚C humidified incubator with 5% CO_2. The cells were subcultured at 80-90% confluency. Cells used in this study were subjected to no more than 20 cell passages.

Evaluation of cell viability by MTT assay. Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) colorimetric assay. U-2OS cells were seeded into 96-well plates at a density of 1.0x10^5 cells/ml in 0.1 ml of medium. The cells were treated with various doses of millimeter wave (MW) for 24 or 48 h. At the end of the treatment, 100 μl MTT [0.5 mg/ml in phosphate buffered saline (PBS)] were added to each well and the samples were incubated for an additional 4 h at 37˚C. The purple-blue MTT formazan precipitate was dissolved in 100 μl DMSO. The absorbance was measured at 570 nm using an Elx808™ absorbance microplate reader (BioTek Instruments, Inc., VT, USA).

Observation of morphologic changes. U-2OS cells were seeded into 6-well plates at a density of 2.0x10^5 cells/well in 2 ml medium. The cells were treated with various doses of MW for 24 or 48 h. Cell morphology was observed using a phase-contrast microscope (Olympus, Japan). The photographs were taken at magnification x100.

Cell treatment. U-2OS cells were digested with 0.25% trypsin and incubated in 25 ml culture flasks at a density of 1x10^5 cells/ml in 4 ml of medium and in 6-well plates at a density of 1x10^5 cells/ml in 2 ml of medium for 24 h. Cells were subsequently divided into 3 groups: control group (normal culture without treatment); MW 30 group (treatment with millimeter wave signal for 30 min each time, 3 times daily); and MW 60 group (treatment with millimeter wave signal for 60 min each time, 3 times daily).

Assessment of apoptosis morphology by Hoechst 33258 staining. After treatment with or without MW, both floating and trypsinized adherent cells were collected, washed once with ice-cold PBS, fixed with 1 ml of 4% paraformaldehyde for 20 min, and washed once with ice-cold PBS. Then, the cells were incubated in 1 ml PBS containing 10 μmol/l Hoechst 33258 at 37˚C for 30 min, washed twice, and observed using fluorescence microscopy with standard excitation filters (Leica Dmirb) in random microscopic fields at magnification x200.

RETRACTED



Figure 1. Millimeter wave (MW) treatment method. (A) Schematic representation of the millimeter waves far field exposure set-up used for investigating MW-induced *in vitro* effects on cell systems cultured in 25-ml culture flasks and 3.5-cm petri dishes (A and B). (B) Enlargement of the culture flasks and petri dish showing all the dielectric interfaces through which millimeter radiation propagates. The multiple stratified dielectric system sketched in (A1 and B1) was used to model the reflection properties of the culture flask and petri dish cell culture system.

RETRACTED

Detection of apoptosis by flow cytometry analysis with Annexin V/PI staining. Following treatment with various doses of MW, apoptosis of U-2OS cells was determined by flow cytometric (FCM) analysis using a fluorescence-activated cell sorting (FACS) caliber (FACSCalibur, Becton-Dickinson, CA, USA) and the Annexin V-FITC Apoptosis Dection Kit II. Staining was performed according to the manufacturer's instructions and as we previously described (30). The percentage of cells in early apoptosis was calculated by Annexin V-positivity and propidium idodide (PI)-negativity, while the percentage of cells in late apoptosis was calculated by Annexin V-positivity and PI-positivity.

Measurement of mitochondrial membrane potential ($\Delta\Psi_m$) by flow cytometry analysis with JC-1 staining. To evaluate for the loss of mitochondrial membrane potential, a hallmark of apoptosis, cells were stained with the fluorescent dye JC-1, which is a cationic dye that exhibits potential mitochondria-dependent accumulation, indicated by a fluorescence emission shift from green to red. In this experiment, $1x10^6$ treated U-2OS cells were resuspended after trypsinization in 0.5 ml of medium and incubated with 10 μg/ml of JC-1 at 37˚C, 5% CO_2, for 15 min. Both red and green fluorescence emissions were analyzed by flow cytometry.

Analysis of cytochrome c staining by flow cytometry. After treatment with various doses of MW for 48 h, cytochrome *c* release was determined by flow cytometry using the InnoCyte™ flow cytometric cytochrome *c* release kit. Cytochrome *c* staining was performed according to the manufacturer's instructions. The results were analyzed using the mean fluorescent intensity (MFI).

Analysis of caspase activation. The activity of caspase-9 and -3 were determined with a colorimetric assay using a colorimetric protease assay, following the manufacturer's instructions and our previous description (35). Briefly, after treated with various doses of MW for 48 h, U-2OS cells were lysed with the manufacturer's provided lysis buffer for 10 min on ice. The lysed cells were centrifuged at 10,000 x g for 1 min. An aliquot (150 μg) of the protein was incubated with 50 μl of the colorimetric tetrapeptides, Leu-Glu-His-Asp (LEHD)-pNA (specific substrate of caspase-9) or Asp-Glue-Val-Asp (DEVD)-pNA (specific substrate of caspase-3) at 37˚C in the dark for 2 h. Samples were read at 405 nm in an absorbance microplate reader (Elx808, BioTek Instruments, Inc., VT, USA). The data were normalized to the activity of the caspases in control cells and presented as fold of control.

RNA extraction and TaqMan real-time PCR analysis. U-2OS cells were seeded into 25 ml culture flasks at a density of $1x10^5$ cells/ml in 4 ml of medium and treated with various doses of MW for 48 h. Total RNA from U-2OS cells was isolated with TRIzol reagent (Invitrogen). A total of 2 μg of total RNA was reverse transcribed, according to the manufacturer's specifications (Promega). For the TaqMan assay, the TaqMan Universal



Figure 2. Effect of MW on the viability of U-2OS cells. U-2OS cells were treated with the indicated dose of MW for 24 h or 48 h. Cell viability was determined by the MTT assay. The data were normalized to the viability of the untreated control cells (100%). Data are averages with SD (error bars) from at least three independent experiments. *P<0.05, **P<0.01, significant versus control cells.

PCR Master Mix Kit (Applied Biosystems) was used. The human receptor activator of Bax, Bcl-2 and GAPDH primer and probe sets were labeled with the 5' reporter dye FAM and the 3' quencher TAMRA (Applied Biosystems). The thermocycling reaction contained the following: 8 μl of H_2O, 10 μl of TaqMan Universal PCR Master Mix, 1 μl of primer and probe set, and 1 μl of cDNA. The reactions were run on the ABI PRISM 7500 Sequence Detection System (Applied Biosystems). The amplification program was as follows: 50˚C for 2 min, 95˚C for 10 min, followed by 40 cycles of 92˚C for 15 sec, and 60˚C for 1 min. The efficiency of the TaqMan assays was determined by assaying serial 10-fold dilutions, ranging from 10^0 to 10^6, of target cDNA. With standard analysis parameters of baseline set between cycle threshold 3 and 15 and the ΔR_n (threshold) set at 0.1, a standard curve of mean cycle threshold for three replicates at each dilution vs $\log_{10}$ amount of cDNA was determined (R^2 = 0.9985). The relative concentration of the mRNA was based on three triplicates normalized to their GAPDH value. The data are shown as fold compared with the control.

Western blot analysis. U-2OS cells were seeded into 25 ml culture flasks at a density of 1x10^5 cells/ml in 4 ml of medium and treated with various doses of MW for 48 h. The treated cells were lysed with mammalian cell lysis buffer containing protease and phosphatase inhibitor cocktails, and the lysates were separated by 12% SDS-PAGE gel under a reducing condition using 100 V for 1 h. The proteins were then electrophoretically transferred onto nitrocellulose membranes using the iBlot Western detection stack/iBlot dry blotting system (Invitrogen). Membranes were blocked for 30 min with agitation at RT in SuperBlock T20 (TBS) blocking buffer (Thermo Scientific, Rockford, IL). Membranes were washed in TBS with 0.25% Tween-20 (TBST) and exposed to primary antibodies against Bcl-2 or Bax (1:1000, Cell Signaling Technology) overnight at 4˚C with rocking. β-actin (1:1000, Cell Signaling Technology) was also measured as an internal control for protein loading. After membranes were washed in TBST, secondary horseradish peroxidase (HRP)-conjugated antibodies (anti-rabbit, Cell Signaling Technology) were added at 1:2500 dilution for 1 h at room temperature and the membranes were washed again in TBST. Finally, the antibody-bound protein bands were detected with ECL, and images were taken using a Bio-Rad ChemiDoc XRS+ (Bio-Rad Laboratories, Inc., CA, USA). The grayscale value ratio of the target protein to the internal control was used to measure the relative amount of Bcl-2 and Bax.

Statistical analysis. Data are the means of three determinations and data were analyzed using the SPSS package for Windows

RETRACTED



Figure 3. Effect of MW on the morphological changes of U-2OS cells. U-2OS cells were treated with the indicated dose of MW for 24 h or 48 h and morphological changes were observed using phase-contrast microscopy. The photographs were taken at magnification x100. Images are representative of three independent experiments.



Figure 4. Effect of millimeter wave (MW) on the apoptosis of U-2OS cells. After treatment with or without MW for 48 h U-2OS cells were collected and stained with Hoechst 33258 staining observed under fluorescence microscope and Annexin V/PI followed by FCM analysis. (A) MW-mediated cell apoptosis morphologic changes were examined by Hoechst 33258 staining and observed under a fluorescence microscope at magnification x200. The apoptotic cells detected by the fluorescence microscopy displayed condensed and fragmented nuclei, shrinkage of cell volume in a concentration-dependent manner. (B) Apoptosis analysis in U-2OS cells was assessed by Annexin V/PI double staining. After cells were exposed to three desired concentrations of MW for 48 h, respectively, the attached and detached cells were collected. Following staining with Annexin V and PI, cells were subjected to flow cytometer analysis. Representative FCM analysis scatter-grams of Annexin V/PI staining display four different cell populations: double-negative stained cells (LL, lower left) representing the live cell population; Annexin V-positive/PI-negative stained cells (LR, lower right) and Annexin V/PI double-positive stained cells (UR, upper right) representing early apoptosis and late apoptosis, respectively; Annexin V-negative and PI-positive stained cells (UL, upper left) representing dead cells. (C) FCM results are expressed as mean ± SD of three independent experiments. *P<0.05, **P<0.01, compared with the control group. $^{\triangle}$P<0.05, $^{\triangle\triangle}$P<0.01, compared with the MW 30 group.

(Version 13.0). Statistical analysis of the data was performed with Student's t-test and ANOVA. Differences with P<0.05 were considered statistically significant.

Results

MW inhibits the growth of U-2OS cells. The effect of MW on the viability of U-2OS cells was determined by MTT assay. As shown in Fig. 2, MW decreased the viability of U-2OS cells in a time- and dose-dependent manner. The cell viability was decreased to 54.4% at the highest dose of MW (treated with millimeter wave signal for 60 min each time, 6 times in 48 h) in this study. To further verify these results, we evaluated the effect of MW on U-2OS cell morphology via phase-contrast microscopy, since cell morphology in culture is indicative of the healthy status of the cells. As shown in Fig. 3, untreated U-2OS cells appeared as cobblestone, whereas after treated with various doses of MW for 24 or 48 h many of the cells became rounded, bright and shrunken, and detached from each other or floated in the medium. The phenomenon was much more obviously in MW 60 group treated with MW for 48 h. Taken together, these data demonstrate that MW inhibits the growth of U-2OS cells. Therefore, treatment with millimeter wave signal for 60 min each time, 3 times daily (MW 60) and 48 h were used as the inducing dose and time in the following experiments.

MW induces apoptosis in U-2OS cells. To determine whether the cell-growth suppressive effect of MW is due to apoptosis and to observe the morphologic characteristics of apoptosis, cells were stained with Hoechst 33258 after MW 60 treatment for 48 h, and detected by fluorescence microscopy. In the study, we found that control cells showed distribution of the stain and round homogeneous nuclei feature, while apoptotic cells increased gradually in a dose-dependent manner and displayed typical changes including reduction of cellular volume, staining bright and condensed or fragmented nucleus (Fig. 4A). For a further

RETRACTED



Figure 5. Effect of millimeter wave (MW) on the loss of mitochondrial membrane potential in U-2OS cells. U-2OS cells were treated with or without MW for 48 h and stained with JC-1. (A) Representative results from JC-1 FCM analysis. (a) JC-1 fluorescence was seen in both the FL-2 and FL-1 channels (UR) in the majority of untreated control cells. A small percentage of the control cells fluoresced in the FL-1 channel and lacked fluorescence in the FL-2 channel (LR). (b and c) MW treatment groups resulted in increased number of cells with low red fluorescence (LR) as compared to the untreated cells, indicative of promotion of the alteration in $\Delta\Psi_m$. (B) Results are expressed as mean ± SD of three independent experiments. *P<0.05, **P<0.01, compared with the control group. $^{\triangle}$P<0.05, $^{\triangle\triangle}$P<0.01, compared with the MW 30 group.

RETRACTED

assessment of apoptosis induced by MW, we examined the exposure of phosphatidylserine on the cell surface by Annexin-V/PI staining followed by FACS analysis. In this assay, Annexin V/PI double-negative population (labeled as LL in the FACS diagram) indicates viable cells; Annexin V-positive/PI-negative or Annexin V/PI double-positive population (labeled as LR or UR in the FACS diagram) represents cells undergoing early or late apoptosis, respectively. As shown in Fig. 4B and C, the percent of cells undergoing apoptosis following treatment with MW (including the early and late apoptotic cells) was 12.65±0.822, 28.24±5.27 and 39.43±5.99% in control group, MW 30 group and MW 60 group, respectively (P<0.01, vs. untreated control cells). The MW treated groups showed significantly more apoptosis than the untreated group (P<0.01). The dose-dependent effect was evident as the group that received longer exposure to the MW signal (MW 60 group) demonstrated much greater number of apoptotic cells (P<0.05, vs. MW 30 group).

Effect of MW on the loss of mitochondrial potential ($\Delta\Psi_m$). Next, we used FCM analysis with JC-1 staining to examine the change in mitochondrial membrane potential $\Delta\Psi_m$ after MW treatment. JC-1 accumulates in normal intact mitochondria and forms aggregates. Aggregation of JC-1 results in red fluorescence (590 nm, FL-2). The intensity of the fluorescence is proportional to the mitochondrial membrane potential. Loss of membrane potential leads to conversion of JC-1 to its monomeric form within the cytoplasm. This results in green fluorescence (529 nm, FL-1). Representative results from a single JC-1 assay for each treament group are shown in Fig. 5A. As shown in Fig. 5B, the percent of apoptotic cells (LR quadrand) was 3.95±0.26, 14.66±0.80 and 40.32±1.60% in control group, MW 30 group and MW 60 group, respectively. Compared with the control group, both the MW 30 and MW 60 groups had a greater number of cells with low red fluorescence [FL-2 (LR)] (P<0.01), indicative of a reduction in the $\Delta\Psi_m$ and the induction of apoptosis. A dose-dependent effect was evident as the MW 60 group demonstrated much greater number of cells with low red fluorescence (P<0.05, vs. MW 30 group).

Effect of MW on the release of cytochrome c. To determine the effect of MW treatment on the release of cytochrome *c* from the mitochondria, an FCM assay was used based on the selective permeabilization of the cell membrane while leaving the mitochondrial membrane intact. In this assay, viable cells exhibit staining of cytochrome *c*, whereas cells committed to the apoptotic process do not stain since they release cytochrome *c* from the mitochondria to the cytosol and, subsequently, out of the permeabilized cell. As shown in Fig. 6, the MFI was 42.01±1.14, 27.23±1.41 and 12.61±0.83 in the control group, MW 30 group and MW 60 group, respectively. Compared with the control group, both MW 30 group and MW 60 group release significantly more cytochrome *c* (P<0.01). A dose-dependent effect was evident as the MW 60 group demonstrated much more cytochrome *c* released (P<0.05, vs. MW 30 group).

Effect of MW on the activation of caspase-9 and -3. To identify the downstream effectors in the apoptotic signaling



Figure 6. Effect of millimeter wave (MW) on the release of cytochrome *c* in U-2OS cells. Cells were treated with or without MW for 48 h. The mean fluorescent intensity (MFI) of cytochrome *c* positively stained cells was determined using FCM analysis. Data are the mean ± SD from at least three independent experiments. *P<0.05, **P<0.01, compared with the control group. △P<0.05, △△P<0.01, compared with the MW 30 group.



Figure 7. Effect of millimeter wave (MW) on the activity of caspase-9 in U-2OS cells. Cells were treated with or without MW for 48 h. Caspase-9 activity was determined by a colorimetric assay. The data were normalized to the caspase activities within untreated control cells and presented as fold of control. Data are the mean ± SD (error bars) from at least three independent experiments. *P<0.05, **P<0.01, compared with the control group. △P<0.05, △△P<0.01, compared with the MW 30 group.



Figure 8. Effect of millimeter wave (MW) on the activity of caspase-3 in U-2OS cells. Cells were treated with or without MW for 48 h. Caspase-3 activity was determined by a colorimetric assay. The data were normalized to the caspase activities within untreated control cells and presented as fold of control. Data are presented as the mean ± SD (error bars) of at least three independent experiments. *P<0.05, **P<0.01, significant versus control group. △P<0.05, △△P<0.01, compared with the MW 30 group.

pathway, the activation of caspase-9 and-3 were examined by a colorimetric assay using specific chromophores, LEHD-pNA



Figure 9. Effect of MW treatment on the mRNA expression of Bax and Bcl-2 in U-2OS cells. Cells were treated with or without MW for 48 h. Bax mRNA and Bcl-2 mRNA qnantified by real-time RT-PCR and normalized by their GAPDH in all the experimental groups. Data shown are averages with SD (error bars) from at least three independent experiments. *P<0.05, **P<0.01, significant versus control group. △P<0.05, △△P<0.01, compared with the MW 30 group.



Figure 10. Effect of MW treatment on the protein expression of Bax and Bcl-2 in U-2OS cells. Cells were treated with or without MW for 48 h and the protein expression level of Bax and Bcl-2 was analyzed by Western blotting. β-actin was used as the internal controls. Data are representative of three independent experiments.

(specific substrate of caspase-9) and DEVD-pNA (specific substrate of caspase-3). As shown in Figs. 7 and 8, MW treatment significantly and dose-dependently induced activation of both caspase-9 and -3 in U-2OS (P<0.01, vs. untreated control cells; P<0.05, vs. MW 30 group).

MW regulated the expression of anti-apoptotic Bcl-2 and pro-apoptotic Bax. Bcl-2 family proteins are key regulators of mitochondrion-mediated apoptosis, including anti-apoptotic members such as Bcl-2 and pro-apoptotic members such as Bax. Tissue homeostasis is maintained by controlling the ratio of active anti- and pro-apoptotic Bcl-2 family proteins. Higher Bcl-2-to-Bax ratio by aberrant expression of the proteins is found commonly in various cancers. To further study the mechanism of the MW anti-cancer activity, we performed TaqMan real-time PCR and Western blotting to examine the mRNA and protein expression of Bcl-2 and Bax in MW-treated U-2OS cells. The results of the TaqMan real-time PCR assay showed that MW treatment profoundly increased Bax and reduced Bcl-2 mRNA expression in U-2OS cells (Fig. 9; P<0.01, vs. untreated control cells; P<0.05, vs. MW 30 group); and the pattern of protein expression of Bax and Bcl-2 was similar to their respective mRNA levels (Fig. 10). The above suggest that MW induces

RETRACTED

mitochondrion-dependent apoptosis in U-2OS cells through the regulation of expression of Bcl-2 family proteins.

Discussion

Cancer cells are characterized by an unregulated increase in cell proliferation and/or a reduction in cell apoptosis (17). In addition, disrupted apoptosis contributes to drug resistance of tumor cells, which has become a significant obstacle for the successful management of patients with malignant tumors including osteosarcoma (6). Moreover, many currently used anti-cancer agents contain intrinsic and potent cytotoxicity to normal cells, which limits their long-term use and their therapeutic effectiveness (7). These problems highlight the urgent need for the development of novel cancer chemotherapies. Since physiotherapy, such as millimeter wave (MW), have relatively fewer side-effects as compared to modern chemotherapeutics and have long been used clinically to treat various types of diseases including cancer (13,36-38), finding that naturally occurring agents with pro-apoptotic activities is a promising approach for anti-cancer treatment.

Millimeter wave treatment is a physiotherapy, which has been demonstrated to be clinically effective in treating various types of diseases including cancers (13,14). However, the mode of action for its anti-tumor is still largely unknown. Therefore, before MW can be further developed as an anti-cancer agent, its anti-tumor activity and underlying molecular mechanism need to be elucidated.

Here we report for the first time that the millimeter wave (MW) reduces the viability and inhibits growth of human osteosarcoma U-2OS cells in a dose- and time-dependent fashion. Furthermore, we demonstrated that these effects on U-2OS cells result from the induction of apoptosis by millimeter wave.

Apoptosis is activated through two major pathways. For the intrinsic pathway, death signals are integrated at the level of the mitochondria (therefore, this pathway is also referred to as mitochondrion-dependent). For the extrinsic pathway, death signals are mediated through cell surface receptors. Both pathways eventually lead to the activation of caspases and nucleases, resulting in the destruction of the cell (13,14,17). Our experimental results showed that apoptotic cells induced by MW displayed condensed and fragmented nuclei by Hoechst 33258 staining (Fig. 4A). For the loss of plasma membrane asymmetry is one of the morphologic characteristics of the apoptotic program. In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the plasma membrane, thereby exposing PS to the external cell environment. Annexin V is a 35-36-kDa Ca^{2+}-dependent phospholipid-binding protein that has a high affinity for PS. Annexin V binds to cells with exposed PS. Therefore, flow cytometry with Annexin-V staining was used to further confirmed the results of Hoechst 33258 staining by showing that the important membrane alterations relating to apoptosis in U-2OS cells and the percent apoptosis increased in dose-corresponding manner (Fig. 4B and C). Taken together, these results suggested that millimeter wave indeed induced apoptosis in U-2OS cells. The loss of mitochondrial membrane potential ($\Delta\Psi_m$) is a hallmark of apoptosis. It is an early event preceding phosphatidylserine externalization and coincides with caspase activation (39,40). In healthy cells, the JC-1 dye stains the mitochondria fluorescent red (41). The negative charge established by the intact mitochondrial membrane potential allows this lipophilic dye, bearing a delocalized positive charge, to enter the mitochondrial matrix where it accumulates. When the critical concentration is exceeded, J-aggregates form. These aggregates are fluorescent red (590 nm). In apoptotic cells, the mitochondrial membrane potential collapses, and JC-1 cannot accumulate within the mitochondria. In these cells, JC-1 remains in the cytoplasm in a green fluorescent monomeric form. JC-1-stained apoptotic cells, having primarily green fluorescence (530 nm), are easily differentiated from healthy cells that have red and green fluorescence (42). Using FCM, healthy cells with red JC-1 aggregates are detected in the FL-2 channel and apoptotic cells with green JC-1 monomers are detected in the FL-1 channel. Thus, JC-1-stained cells that fluoresce in the FL-2 and FL-1 channels (UR quadrant) carry mitochondria with a polarized $\Delta\Psi_m$, whreas JC-1-stained cells that fluoresce in the FL-1 channel and not in the FL-2 channel (LR quadrant) carry mitochondria with a depolarized $\Delta\Psi_m$. Therefore, JC-1 dye-based assay was used to evaluate mitochondrial membrane potential in the study. Our data clearly showed that treatment with MW leads to a collapse of mitochondrial membrane potential (Fig. 5).

The mitochondrion-dependent pathway is the most common apoptotic pathway in vertebrate animal cells. Mitochondrial outer membrane permeabilization (MOMP) accompanied by the collapse of electrochemical gradient across the mitochondrial membrane is a key commitment step in the induction of mitochondrion-dependent apoptosis. This is the point of convergence for a large variety of intracellular apoptotic signaling pathways that eventually lead to the release of pro-apoptotic proteins from the mitochondrial intermembrane space, including cytochrome *c*, Smac/DIABLO, and Omi/HtrA2. Released cytochrome *c* activates APAF-1, which oligomerizes to form an apoptosome. This structure, in turn, recruits and activates caspase-9. Activated caspase-9 cleaves and activates executioner caspases, such as caspase-3, and eventually results in apoptosis (39,40,43). Therefore, to evaluate the effect of MW on the mitochondrion-dependent apoptosis pathway, we evaluated the release of cytochrome *c* and the activation of caspase-9 and -3. In this study, we found that MW induces the release of cytochrome *c* and the activation of both caspase-9 and -3 in U-2OS cells in a dose-dependent manner (Figs. 6-8). Thus, MW-induced U-2OS cell death is accompanied by an increase in the release of cytochrome *c* and the activities of caspases-9 and -3, which then stimulates the molecular cascade for apoptosis.

Occurrence of mitochondrial-dependent apoptosis is typically governed by contradicting the Bcl-2 family (44). Bcl-2 is a well-known anti-apoptotic protein that can prevents cytochrome*c* release whereas Bax (Bcl-2-associated X protein) and Bad, pro-apoptotic proteins, enhance cytochrome *c* release from mitochondria into cytosol (45), which is responsible for activating caspase-9, -3 and facilitates apoptosis (46). Therefore, the ratio of Bax to Bcl-2 is a critical for determining the fate of cells. In this study, we demonstrated that MW treatment dose-dependently enhances Bax mRNA expression and reduces Bcl-2 mRNA expression in U-2OS cells (Fig. 9; $P<0.01$, vs. untreated control cells; $P<0.05$, vs. MW 30 group). This indicates that MW induces apoptosis by affecting the ratio of Bax/Bcl-2 at transcriptional level. We further studied the role of MW on the

RETRACTED

expression of proteins involved in the mitochondrial pathway. The results showed that MW treatment up-regulates Bax protein expression and down-regulates Bcl-2 protein expression (Fig. 10), which is in accordance with the pattern of their mRNA expression after MW treatment.

In conclusion, our data for the first time demonstrate that MW inhibits the growth of U-2OS cells and induces U-2OS cell apoptosis via the mitochondrion-dependent pathway. These results suggest that millimeter wave may be a potential novel treatment option for osteosarcoma and other cancers.

Acknowledgements

This work was supported by the Developmental Fund of Chen Keji Integrative Medicine (CKJ2010023).

References

1. Longhi A, Errani C and De Paolis M: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436, 2006.
2. Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085, 2006.
3. Kim SJ, Choi JA, Lee SH, Choi JY, Hong SH, Chung HW and Kang HS: Imaging findings of extrapulmonary metastases of osteosarcoma. Clin Imaging 28: 291-300, 2004.
4. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jurgens H, Gadner H and Bielack SS: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21: 2011-2018, 2003.
5. Federman N, Bernthal N, Eilber F and Tap W: The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 10: 82-93, 2009.
6. De Saint Aubain Somerhausen N and Fletcher CD: Soft-tissue sarcomas: an update. Eur J Surg Oncol 25: 215-220, 1999.
7. Boose G and Stopper H: Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 116: 7-16, 2000.
8. Millenbaugh NJ, Roth C, Sypniewska R, Chan V, Eggers JS, Kiel JL, Blystone RV and Mason PA: Gene expression changes in the skin of rats induced by prolonged 35 GHz millimeter-wave exposure. Radiat Res 169: 288-300, 2008.
9. Zhadobov M, Sauleau R, Le Coq L, Debure L, Thouroude D, Michel D and Le Drean Y: Low-power millimeter wave radiations do not alter stress-sensitive gene expression of chaperone proteins. Bioelectromagnetics 28: 188-196, 2007.
10. Wu GW, Liu XX, Wu MX, Zhao JY, Chen WL, Lin RH and Lin JM: Experimental study of millimeter wave-induced differentiation of bone marrow mesenchymal stem cells into chondrocytes. Int J Mol Med 23: 461-467, 2009.
11. Li XH, DM, Liu XX, Wu MX, Ye HZ, Lin JM, Chen WL and Wu GW: Millimeter wave treatment inhibits NO-induced apoptosis of chondrocytes through the $p38^{MAPK}$ pathway. Int J Mol Med 25: 393-399, 2010.
12. Wang YP, Yuan SL, Chen XH, Yang Y, Song Y and Chen NY: Experimental study of apoptosis and its molecular mechanisms of nasopharyngeal carcinoma cell induced by millimeter wave irradiation. J Infrared Millimeter Waves 20: 283-286, 2001.
13. Usichenko TI, Edinger H, Witstruck T, Pavlovic D, Zach M, Lange J, Gizhko V, Wendt M, Koch B and Lehmann C: Millimetre wave therapy for pain relief after total knee arthroplasty: a randomised controlled trial. Eur J Pain 12: 617-623, 2008.
14. Chen JL: Effect of combination millimeter wave irradiation on hepatic cellular cancer patient. Int J Infect Dis 13 (Suppl. 1): S62, 2009.
15. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
16. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
17. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007.
18. Cory S and Adams JM: The Bcl-2 family: regulators of the cellular life-of-death switch. Nat Rev Cancer 2: 647-656, 2002.
19. Vaux DL and Korsmeyer SJ: Cell death in development. Cell 96: 245-254, 1999.
20. Gross A, McDonnell JM and Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
21. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ: Movement of Bax from the cytosol to mitochondria. J Cell Biol 139: 1281-1292, 1997.
22. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB and Kormeryer SJ: tBid, a membrane-targeted death ligand, oligomerizes Bak to release cytochrome c. Genes Dev 14: 2060-2071, 2000.
23. Antonsson B, Montessuit S, Lauper S, Eskes R and Martinou JC: Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 345: 271-278, 2000.
24. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
25. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI and Jones DP: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997.
26. Zou H, Li Y, Liu X and Wang X: An APAF1-cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274: 11549-11556, 1999.
27. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, *et al*: Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267: 1506-1510, 1995.
28. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC and Korsmeyer SJ: Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426: 671-676, 2003.
29. Veis DJ, Sorenson CM, Shutter JR and Korsmeyer SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75: 229-240, 1993.
30. Thomenius MJ, Wang NS, Reineks EZ, Wang Z and Distelhorst CW: Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. J Biol Chem 278: 6243-6250, 2003.
31. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R and Martinou JC: Inhibition of Bax channel-forming activity by Bcl-2. Science 277: 370-372, 1997.
32. Youle RJ and Strasser A: The Bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
33. Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene 27: 6398-6406, 2008.
34. Kitada S, Pedersen IM, Schimmer AD and Reed JC: Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21: 3459-3474, 2002.
35. Wu GW, Sferra TJ, Chen XZ, Chen YQ, Wu MX, Xu HF, Peng J and Liu XX: Millimeter wave treatment inhibits the mitochondrion-dependent apoptosis pathway in chondrocytes. Mol Med Rep 4: 1001-1006, 2011.
36. Bancroft MI: Physiotherapy in cancer rehabilitation: a theoretical approach. Physiotherapy 89: 729-733, 2003.
37. Dorey G: Physiotherapy for the relief of male lower urinary tract Symptoms: A Delphi study. Physiotherapy 86: 413-426, 2000.
38. Lauridsen MC, Christiansen P and Hessov I: The effect of physiotherapy on shoulder function in patients surgically treated for breast cancer: a randomised study. Acta Oncol 44: 449-457, 2005.
39. Mantymaa P, Siitonen T, Guttorm T, *et al*: Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol 108: 574-581, 2000.
40. Korper S, Nolte F, Rojewski MT, Thiel E and Schrezenmeier H: The K^+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca^{2+} in $CD34^+$ cell line KG-1a. Exp Hematol 31: 815-823, 2003.

RETRACTED

41. Cossarizza A, Baccarani-Contri M, Kalashnikova G and Franceschi C: A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3' tetraethylbenzimidazolylcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 197: 40-45, 1993.
42. Smiley ST, Reers M, Mottola-Hartshorn C, *et al*: Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88: 3671-3675, 1991.
43. Eskes R, Desagher S, Antonsson B and Martinou JC: Bid induces the ligomerization and insertion of bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929-935, 2000.
44. Adams JM and Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26: 61-66, 2001.
45. Fujio Y, Nguyen T, Wencker D, Kitsis RN and Walsh K: Akt promotes survival of cardiomyocytes in vitro and protects against lschemia-reperfusion injury in mouse heart. Circulation 101: 660-667, 2000.
46. Brown GC and Borutaite V: Nitric oxide, cytochrome c and mitochondria. Biochem Soc Symp 66: 17-25, 1999.

RETRACTED